Similar articles for PMID: 16595507

Year	Number of Results
1977	1
1986	1
1988	3
1989	3
1990	4
1991	3
1992	6
1993	6
1994	11
1995	4
1996	4
1997	10
1998	10
1999	17
2000	16
2001	15
2002	18
2003	22
2004	13
2005	23
2006	15
2007	10
2008	10
2009	11
2010	9
2011	12
2012	11
2013	15
2014	17
2015	13
2016	8
2017	12
2018	15
2019	17
2020	12
2021	15
2022	5
2023	1
2024	0

1

Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.

Kelly MP, Lee FT, Smyth FE, Brechbiel MW, Scott AM. Kelly MP, et al. J Nucl Med. 2006 Apr;47(4):716-25. J Nucl Med. 2006. PMID: 16595507 Free article.

2

Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.

Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. Clarke K, et al. Clin Cancer Res. 2000 Sep;6(9):3621-8. Clin Cancer Res. 2000. PMID: 10999754

3

Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.

Kelly MP, Lee FT, Tahtis K, Smyth FE, Brechbiel MW, Scott AM. Kelly MP, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5604s-5612s. doi: 10.1158/1078-0432.CCR-07-1071. Clin Cancer Res. 2007. PMID: 17875796

4

Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.

Lee FT, Mountain AJ, Kelly MP, Hall C, Rigopoulos A, Johns TG, Smyth FE, Brechbiel MW, Nice EC, Burgess AW, Scott AM. Lee FT, et al. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7080s-7086s. doi: 10.1158/1078-0432.CCR-1004-0019. Clin Cancer Res. 2005. PMID: 16203806

5

In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice.

Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. Clarke K, et al. Cancer Res. 2000 Sep 1;60(17):4804-11. Cancer Res. 2000. PMID: 10987290

6

Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.

Kelly MP, Lee ST, Lee FT, Smyth FE, Davis ID, Brechbiel MW, Scott AM. Kelly MP, et al. Prostate. 2009 Jan 1;69(1):92-104. doi: 10.1002/pros.20856. Prostate. 2009. PMID: 18942092 Free PMC article.

7

Combined modality radioimmunotherapy. Promise and peril.

Burke PA, DeNardo SJ, Miers LA, Kukis DL, DeNardo GL. Burke PA, et al. Cancer. 2002 Feb 15;94(4 Suppl):1320-31. doi: 10.1002/cncr.10303. Cancer. 2002. PMID: 11877763 Free article.

8

Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.

Crow DM, Williams L, Colcher D, Wong JY, Raubitschek A, Shively JE. Crow DM, et al. Bioconjug Chem. 2005 Sep-Oct;16(5):1117-25. doi: 10.1021/bc0500948. Bioconjug Chem. 2005. PMID: 16173788

9

Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.

Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Burke PA, et al. Cancer Res. 2002 Aug 1;62(15):4263-72. Cancer Res. 2002. PMID: 12154028

10

Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.

Denardo SJ, Richman CM, Kukis DL, Shen S, Lamborn KR, Miers LA, Kroger LA, Perez EA, Denardo GL. Denardo SJ, et al. Anticancer Res. 1998 Nov-Dec;18(6A):4011-8. Anticancer Res. 1998. PMID: 9891439

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

375 results

Results by year